Menu

FDA Seeks to Block Two Unregulated Stem Cell Clinics

Two patients became legally blind after receiving treatments at the facilities.

May 11, 2018
Jim Daley

FLICKR, FDA

On Wednesday (May 9), the Food and Drug Administration announced that it is requesting injunctions in federal courts against two stem cell clinics, one based in California and another in Florida, that would force them to stop operating. Two former patients are suing the cell shops, saying they went blind after receiving treatments at them, according to The Washington Post.

See “Women Lose Vision After Stem Cell Treatment

“Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk,” says FDA Commissioner Scott Gottlieb in a press release. “In some instances, patients have suffered serious and permanent harm after receiving these unapproved products. In the two cases filed today, the clinics and their leadership have continued to disregard the law and more importantly, patient safety.”

The FDA warned US Stem Cell in Florida and the California Stem Cell Treatment Center that it had “serious concerns” about their practices in August 2017, according to STAT News. In the press release, the FDA says the clinics “did not address the violations” described in the warning letter.

See “Texas Stem Cell Law Opens Door for Controversial Treatments

In a statement, US Stem Cell says it intends “to vigorously defend” the lawsuit. “My entire career has been dedicated to studying and developing treatments utilizing the body’s own natural ability to heal,” says Kristin Comella, the clinic’s chief science officer, in a statement quoted in The Post. “I remain steadfast that no government agency should deprive individuals of their right to harness the cells that exist in their body.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.